Karuna Therapeutics, Inc. KRTX
Set alert
At close · Mar 15
52-week range unavailable
- Open
- 329.75
- Prev close
- 329.83
- Mkt cap
- 12.60B
- Vol
- 1.28M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 329.75
- High
- 329.97
- Forward P/E
- -36.49
- Beta
- 1.15
- Short ratio
- 3.60
- Inst. own
- 86.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 2, 2024
- 50-d avg
- 317.71
- 200-d avg
- 230.08
- 1y target
- 324.17
Key statistics
- Market cap
- 12.60B
- Enterprise value
- 11.34B
- Trailing P/E
- 0.00
- Forward P/E
- -36.49
- PEG ratio
- 0.33
- Price / sales
- 19264.94
- Price / book
- 10.01
- EPS (TTM)
- -11.74
- Beta
- 1.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 654.00K
- Revenue growth
- -100.00%
- Free cash flow
- -223.64M
- Total cash
- 1.26B
- Total debt
- 16.69M
- Return on equity
- -36.44%
- Shares outstanding
- 38.20M
- Short % of float
- 6.03%
- 50-day average
- 317.71
- 200-day average
- 230.08
Analyst view
Consensus: hold
- Target (low)
- 260.00
- Target (mean)
- 324.17
- Target (high)
- 330.00
Next earnings
May 2, 2024
Expected May 2, 2024. Consensus EPS estimate -3.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 2, 2024 | Mar 1, 2024 | -3.00 | — | — | — |
| Feb 22, 2024 | Dec 1, 2023 | -2.64 | — | — | — |
| Nov 2, 2023 | Sep 1, 2023 | -2.74 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -2.76 | — | — | — |
| May 4, 2023 | Mar 1, 2023 | -2.86 | — | — | — |
| Feb 23, 2023 | Dec 1, 2022 | -2.23 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 27, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 7, 2023 | B of A Securities | main | Buy | Buy |
| Aug 21, 2023 | Cantor Fitzgerald | reit | Neutral | Neutral |
| Aug 21, 2023 | Wells Fargo | init | — | Overweight |
| Aug 3, 2023 | Morgan Stanley | reit | Overweight | Overweight |
| Aug 3, 2023 | RBC Capital | main | Outperform | Outperform |
About Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- karunatx.com
News
- Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
- Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
- KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
- Bullish Continuation in '24? 3 Market Areas to Watch
- 5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
- Cramer names biopharma companies to watch as industry mergers start to pile up
- KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
- Yes Virginia, There Is a Santa Claus Rally
- Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
- Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'
Your note
Sign in to keep a note on KRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRANNAN STEPHEN K | Officer | Sale | Mar 7, 2024 | 42,604 |
| BROWN JASON PARKER | Chief Financial Officer | Stock Award(Grant) | Sep 28, 2023 | 21,445 |
| COUGHLIN CHRISTOPHER J | Director | Stock Award(Grant) | Jun 19, 2023 | 990 |
| HEALY JAMES I | Director | Stock Award(Grant) | Jun 19, 2023 | 1,414,640 |
| IGNELZI TROY A | Chief Financial Officer | Sale | Aug 21, 2023 | 30,487 |
| JONAS JEFFREY M | Director | Sale | Aug 31, 2023 | 990 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.91% | 5,616,588 | 1.22B | Jun 29, 2023 |
| Capital International Investors | 10.60% | 3,992,549 | 865.78M | Jun 29, 2023 |
| Vanguard Group Inc | 8.22% | 3,097,899 | 671.78M | Jun 29, 2023 |
| Price (T.Rowe) Associates Inc | 7.07% | 2,661,492 | 577.14M | Jun 29, 2023 |
| T. Rowe Price Investment Management, Inc. | 6.58% | 2,479,035 | 537.58M | Jun 29, 2023 |
| Blackrock Inc. | 4.95% | 1,864,636 | 404.35M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund Of America Inc | 6.46% | 2,433,857 | 527.78M | Jun 29, 2023 |
| Fidelity Growth Company Fund | 3.38% | 1,271,966 | 238.82M | Aug 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.67% | 1,006,660 | 218.29M | Jun 29, 2023 |
| Vanguard Small-Cap Index Fund | 2.18% | 821,610 | 178.17M | Jun 29, 2023 |
| Vanguard Specialized-Health Care Fund | 2.03% | 765,799 | 152.98M | Jul 30, 2023 |
| Price (T.Rowe) Health Sciences Fund | 1.96% | 736,804 | 159.78M | Jun 29, 2023 |